

Australia's BCAL Diagnostics commences operations in US

28 August 2024 | News

BCAL US research laboratory to commence operations from 2 September



BCAL Diagnostics, based in Sydney, Australia, has established a subsidiary in the US and will commence operations out of its North Carolina laboratory on the 2nd of September.

The expansion into the US is essential to help the company establish a presence in the US market ahead of the launch of their breast cancer blood screening solution, BREASTEST, which is expected for 2025.

The US programme also offers BCAL an opportunity to accelerate and validate new products on US patient centric data and gain an in-country understanding of the US diagnostics market.

BCAL US will be headed by Dr Klaus-Peter Adam, the former Chief Technology Officer of Precion Inc., a partner of BCAL. The subsidiary will also acquire essential equipment from Precion to fit into the new lab.

This announcement comes two months after the company closed a successful \$10.5 million raise, which will help fund the new operation.